

ANTIMICROBIALS AND NON-HEALING WOUNDS: AN UPDATE

INCLUDING A CONCISE
APPROACH TO
TREATING POTENTIALLY
INFECTED WOUNDS



Antimicrobials and Non-healing Wounds: An Update

Sebastian Probst

DClinPrac, MScN, RN, Professor of Tissue and Wound Care, Geneva School of Health Sciences, HES-SO University of Applied Sciences and Arts Western Switzerland, Geneva, Switzerland
Care Directorate, University Hospital Geneva, Geneva, Switzerland
Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia

Jan Apelqvist

MD, PhD, Senior Consultant, Department of Endocrinology, University Hospital Malmö, Sweden
Associate Professor, Department of Clinical Science, University of Lund, Sweden

Thomas Bjarnsholt

MD, PhD, Professor, Costerton Biofilm Centre, University of Copenhagen, Copenhagen, Denmark
Head of Molecular Diagnostic Laboratory, Copenhagen University Hospital, Department of Clinical Microbiology, Copenhagen, Denmark

Benjamin A. Lipsky

MD, Professor Emeritus, University of Washington, Seattle, USA
Member, Green Templeton College, University of Oxford, United Kingdom

Karen Ousey

MA, PhD, Professor, Director for the Institute of Skin Integrity and Infection Prevention, University of Huddersfield, Huddersfield, England, United Kingdom

Edgar J.G. Peters

MD, PhD, Associate Professor, Department of Internal Medicine, Section of Infectious Diseases, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Infection and Immunity Institute, Amsterdam, The Netherlands

Corresponding author:

Sebastian Probst
sebastian.probst@hesge.ch

Editorial support and coordination:

Lise Philipsen, EWMA Secretariat

This article should be referenced as:

Probst S, Apelqvist J, Bjarnsholt T, Lipsky BA, Ousey K, Peters EJG. Antimicrobials and Non-healing Wounds: An Update. J Wound Management, 2022;23(3 Sup1):S1-S33.
DOI:10.35279/jowm2022.23.03.sup01

The EWMA AMS programme is supported by an unrestricted educational grant from Convatec, Essity, Flen Health, Hydrofera Blue, Mölnlycke and PolyMem.

© EWMA 2022

Copyright of published material and illustrations is the property of the European Wound Management Association. However, provided prior written consent for their reproduction, including parallel publishing (e.g. via repository), obtained from EWMA via the Editorial Board of the Journal, and proper acknowledgement, such permission will normally be readily granted. Requests to produce material should state where material is to be published, and, if it is abstracted, summarised, or abbreviated, then the proposed new text should be sent to Journal of Wound Management Editor for final approval. Although EWMA has taken great care to ensure accuracy, EWMA will not be liable for any errors of omission or inaccuracies in this publication.

Published by the European Wound Management Association, Nordre Fasanvej 113, 2, 2000 Frederiksberg, Denmark
Web: www.ewma.org. Email: ewma@ewma.org

Contents

1. Introduction and aim	4
2. The principal role of bioburden in wounds	6
2.1 Biofilms	
2.2 Questions covered in 2013 & updated statements	
2.3 Overall conclusions	
2.4 Implications for clinical practice	
3. Treatment	10
3.1 Introduction	
Topical antibiotics	
Antiseptics	
3.2 Indications for treatment	
To prevent infection	
Resolution of infection	
Strengths and limitations of the current evidence base	
3.3 Questions covered in 2013 & updated statements	
What type of evidence should we be looking for?	
Infection as endpoint	
Strengths and limitations of the current evidence base	
3.4 Overall conclusions & implications for clinical practice	
4. The patient perspective	15
4.1 Introduction	
4.2 The clinical needs of individuals with non-healing wounds	
Safety of patients with wounds	
Patient involvement	
4.3 Questions covered in 2013 & updated statements	
4.4 Overall conclusions & implications for clinical practice	
5. Economics & organisation of care	18
5.1 Introduction: the burden of non-healing wounds	
5.2 Questions covered in 2013 & updated statements	
5.3 Overall conclusions & implications for clinical practice	
6. Future perspectives & antimicrobial stewardship	21
6.1 Introduction	
6.2 Questions & statements	
6.3 Overall conclusions	
7. A concise approach to treating potentially infected wounds	26
8. Conclusion	27
9. Glossary	28
10. References	30

1. Introduction and aim

The global prevalence of non-healing wounds (also referred to as chronic wounds, hard-to-heal wounds or complex wounds) with mixed aetiologies has been estimated at 2.21 per 1000 population (1). The number of individuals developing non-healing wounds is increasing due to changing lifestyles (2) and an ageing population (3). These wounds therefore present a major social and financial burden, not only for the affected individuals and their families, but also for healthcare systems around the world (4).

This document is aimed at two major audiences: healthcare providers of all types, who are tasked with providing hands-on care to patients with wounds, and researchers, who may derive ideas for future investigations from our suggestions and support when applying to funding agencies for research projects. The purpose of the document is to provide an update on existing knowledge on antimicrobials, including a general clinical approach to prescribing antimicrobials. It is not a guideline document and does not deal with particular topical products with antimicrobial agents.

Wound infections are common in clinical practice and, while the most common etiologic agents are bacteria, fungi and occasionally other microorganisms cause some wound infections (5). Because infection is one of the most frequent factors associated with stalled wound healing, prevention of infection and the proper use of antimicrobial agents is key in wound management. We recognise that many types of microorganisms can infect wounds, but bacterial species dominate as etiologic agents. Thus, nearly all antimicrobials used for treating wounds are aimed at bacteria, and these agents are what we discuss in this document.

The growing problem of antimicrobial resistance (AMR) is an urgent issue requiring an immediate, global, coordinated action plan (6,7). The word ‘antimicrobial’ is an umbrella term referring to disinfectants, antiseptics, antivirals, antifungals, antiparasitics and antibiotics used to inhibit the growth of or kill various microorganisms (8,9). AMR refers to the phenomenon of microorganisms developing mechanisms by which they are no longer susceptible to various agents, rendering them ineffective for treatment. Effective antimicrobial agents (including antiseptics and antibiotics) are essential for protecting patients against infection in many settings and situations, including post-operative wound infection and the management of various types of non-healing wounds. Worldwide evidence has shown that common wound pathogens are increasingly becoming resistant to antibiotics (10). It is therefore necessary that all wound care specialists employing systemic or topical antimicrobials should be aware of, and adhere to, the principles of appropriate use. To support the clinical decision-making process in this setting, the European Wound Management Association (EWMA) has undertaken this update of a document reviewing an approach to Antimicrobials and Non-healing Wounds, initially published in 2013 (11).

The aims of this update document are to:

- Highlight current knowledge regarding the use of antimicrobial agents, particularly in non-healing wounds
- Discuss new information and progress in this field since 2013
- Offer recommendations for future actions

- Provide practical guidance for clinical practice concerning the appropriate use of antibiotics and antiseptics in wound management

This update is structured according to the 2013 Antimicrobials and Non-healing Wounds document (11) with the following headings: the principal role of bioburden in wounds, treatment, the patient perspective and economics and organisation of care. Under these headings, the paper provides an update on the knowledge achieved in each field

and updated answers to the questions raised in the 2013 publication. In addition, this document includes a new section on future perspectives and antimicrobial stewardship, to highlight the strategies that have generally been adopted within this field since 2013 and outline their impact on the use of antimicrobial agents in wound management. Finally, this document includes a revised algorithm on how to treat with antimicrobials in wound management (12).

2. The principal role of bioburden in wounds

Thomas Bjarnsholt

The Antimicrobials and Non-healing Wounds document from 2013 (11) posed several questions regarding the role of microorganisms in wounds and how they may potentially delay healing. Issues discussed included those related to the balance between infecting bacteria and immune defences, and the possible consequences of this interaction on wound healing.

We argued that the factors that determine the outcome of host–pathogen interactions are incompletely understood (13,14). The impact of microbial cells and their products on healing have still not been fully elucidated; furthermore, the factors leading to the transition of an acute wound into a chronic wound are only partially explained at present.

2.1 Biofilms

Bacteria exist either as planktonic organisms or in aggregates called biofilms (15). In past decades, the presence of planktonic bacteria has been correlated with acute infections and biofilms to chronic infections (16–18). Yet recent publications challenge this paradigm. For example, the distribution of single cells and aggregates does not seem to be different in cases of acute, compared to chronic, pneumonia. However, there seems to be a difference in the metabolism of the infecting bacteria, with acute infections being dominated by more metabolically active bacteria compared to chronic infection (19). Non-healing wounds have also been shown to harbour vast numbers of single cells (manuscript in preparation), but we

do not know what role they play in relation to aggregated bacteria.

Most of our knowledge about biofilms is derived from *in vitro* studies, where tolerant bacteria are dormant and closely resemble the stationary growth of planktonic bacteria. This dormancy is thought to be established by increasing gradients of nutrients and oxygen as the layers of bacteria increase (20). The matrix of the biofilm also plays a role. While it is not a ‘bullet-proof’ physical shell surrounding the bacteria, the matrix components chelate and/or neutralise certain antimicrobial agents, but allow some to penetrate more freely (21).

Reduced susceptibility of bacteria in biofilms to antiseptics, antibiotics and most host defence mechanisms is correlated to the development of bacterial aggregation, which is referred to as ‘tolerance’. Tolerance is distinct from resistance, which is usually caused by the acquisition by the microorganisms of determinants that regulate active mechanisms that directly diminish the action of antimicrobial agents and allow cell division and microbial growth. Tolerance enables the cells in biofilms to withstand long-term exposure to antimicrobial agents without a loss of viability. Many antibiotics show high levels of antimicrobial activity only on metabolically active bacteria.

Despite the publication of numerous papers on bioburden and biofilms in acute and chronic wounds over the past decade, this scientific field has not moved much beyond what we knew in 2013.

2.2 Questions covered in 2013 & updated statements

The following section includes the key questions concerning the role of bioburden in wounds from the 2013 document (11), for which there are new findings, leading to adjustments of the statements provided in the original document.

Q1: Do bacteria impair wound healing in a non-infected, non-healing wound?

The precise role of bacteria in wounds and their implications for wound healing is still not understood. However, the question, as it was posed in 2013 regarding the presence of bacteria without infection, but still causing delayed wound healing, is probably no longer valid. It was stated that bacteria could delay wound healing even in the absence of clinical signs of infection. However, it now appears that, if wound healing is delayed, an inflammatory response is on-going, even if it is not obvious macroscopically. New diagnostic approaches are encouraged, as bacteria without an inflammatory response would not delay wound healing.

Q2: Is the number of a specific bacterium per gram (or cm³) of tissue an adequate indicator of infection in all types of wounds?

The term critical colonisation has been abandoned in the recent clinical guidelines (22), and we know that bacteria are very heterogeneously distributed. Therefore, a cut-off number of bacteria in a sample is not representative of the entire wound (22) and is not an adequate definition of the presence of infection.

Q3: Should microbial cells always be eliminated from a wound, and do we know enough to set an indication for topical antimicrobial intervention from a microbiological perspective?

The conclusion from 2013 is still valid; that is, we do not yet understand the role of the presence

of different bacterial or fungal species on wound healing. However, we believe that the presence in tissue of microorganisms considered to be classical pathogens (e.g., *Staphylococcus aureus*) generally indicates infection and should be treated with antimicrobials.

Q4: Is the type or virulence of bacteria important?

The role of various bacterial or fungal species in impairing wound healing has not yet been clarified.

Q5: What is critical colonisation?

The term critical colonisation has now been abandoned (see Question 2). However, as suggested in 2013, further investigation into the relationship between bioburden, inflammatory response, clinical manifestations and outcomes is still needed.

Q6: Is the removal of microorganisms from wounds a sufficient endpoint to assess the efficacy of the use of antimicrobials in wounds?

Reducing the microbial load is theoretically an appropriate endpoint, but it faces difficulties in practice. Using quantitative bacteriology as an endpoint for the efficacy of an antimicrobial agent is hampered by the heterogeneous distribution of bacteria, and by the practical difficulties of conducting this measurement in clinical microbiology laboratories. It is extremely difficult to monitor the reduction of bacteria during treatment using wound swabs, or even tissue biopsies. Thus, quantitatively monitoring microorganism counts has not been shown to be useful in determining the efficacy of antimicrobials for treating wounds.

Q7: Does the presence of a biofilm itself influence wound healing?

The role of biofilms in impairing the healing of wounds is still controversial, but data suggest that bacteria generating an inflammatory response probably do impair wound healing. Non-healing




Figure 1: Number of PubMed-indexed publications using the word biofilm* 2013–2021.

Source: PubMed.gov, generated by the author.

wounds contain bacteria both in biofilms and as single cells, but why they are not eradicated and what role they play remain open questions.

Q8: Is the presence of a biofilm in a wound always undesirable?

This is still an emerging area of research, and we may have to rethink how we investigate the role of biofilms in non-healing wounds and chronic infections in general.

Q9: How can bacteria in biofilms be removed from wounds?

It might not be the aggregation of bacteria per se that is the issue, but rather the physiology of the bacteria and the microenvironment of the wound bed that leads slow-growing or dormant bacteria not to be eradicated by antimicrobial agents (23).
Q10: Is there any antimicrobial agent that is not expected to select for resistance or tolerance in bacteria in the wound?

Eventually, it is likely that resistance will develop against any topical antimicrobial. Continuous and pro-active monitoring for resistance is therefore a must. In experiments, bacteria treated with honey,

povidone iodine, octenidine, polyhexanide and chlorhexidine in vitro have not been shown to develop resistance, but more research is needed (11).

2.3 Overall conclusions

Despite an ever-increasing number of publications (see Figure 1) related to the presence and possible treatment of biofilms in wounds, there has not been any significant progress in the field.

The reasons for this lack of progress are not fully understood, but we suspect that the way we envision bacteria in the wound bed could be at least partly to blame. There seems to be too great a focus on extrapolating data from studies of laboratory-grown biofilms and their behaviour to bacteria in the wound bed. The in vitro biofilms and experimental systems are not wrong, but they do not fully encompass the wound microenvironment (24,25,26). We also encounter problems with the treatment of non-healing wounds because the antibiotic standard minimal inhibitory concentration (MIC) is not transferable to wounds and in vitro biofilm susceptibility only reveals that the bacteria are more tolerant (27).

In conclusion, some major challenges that remain are:

- Our experimental models do not adequately assess the biogeography and dynamics of a wound bed (23). It is easy to identify the mismatch between experimental models and a real infection, but it is extremely difficult and complicated to dissect the biology of infections.
- The field needs to initiate new approaches to avoid repeating errors made in the 2013 conclusions in future updates. To support this goal, we suggest:
 - Focusing more on the infectious microenvironment (i.e., the physiology of the infecting bacteria)
 - Realising that we must design our experiments to simulate actual infection, instead of basing these only on the experimental models available

2.4 Implications for clinical practice

Clinical practice is often influenced by a lack of knowledge regarding the role of biofilms in non-healing wounds. This means that most clinicians still treat the patient on the basis of wound culture results. At the same time, at least one recent survey indicates that healthcare professionals have adopted an in vitro-based mental model for how bacteria grow in non-healing wounds (26). In addition, industry and basic researchers seem dedicated to an in vitro-influenced approach to developing strategies for wound healing.

3. Treatment

Edgar Peters

3.1 Introduction

This chapter covers existing controversies from the perspective of the providers of antimicrobial treatment and other aspects of wound care.

Signs and symptoms of inflammation caused by tissue invasion of micro-organisms define the presence of wound infection. High-level evidence for topical antiseptics and topical antibiotics derived from meta-analyses and randomised clinical trials is limited. An analysis of 149 Cochrane systematic reviews assessed the strength of evidence presented in 44 of these reviews and demonstrated that only for some local and systematic wound care interventions could strong conclusions about effectiveness be drawn (28). Similar conclusions were drawn in more recent systematic reviews of the use of topical antimicrobial agents in diabetic foot ulcers (DFUs) and burns (29); there are only few available studies, usually of low quality, on the efficacy of topical antimicrobial agents in diabetic foot wounds and burns. Antimicrobial efficacy is currently almost exclusively evaluated *in vitro* in bacteria in planktonic phenotypes (30). Standardised methods for evaluating antimicrobials and antiseptics in wound biofilms have been developed, but are not being used in patient care. Below, we discuss the topical use of antibiotics (i.e., antimicrobial compounds that can be used both topically and systemically) and antiseptics (i.e., antimicrobial compounds that can only be used topically).

Topical antibiotics

Guidelines for using antibiotics both therapeutically and prophylactically have been developed (31–33), but the quality of the evidence used to formulate these guidelines is of low quality (34).

Topical antibiotics are prescribed more often than suggested in the guidelines (35). This leads to higher consumption of antibiotics, and the high consumption of antibiotics is associated with a high degree of antibiotic resistance (36). The continued emergence of antibiotic-resistant strains and limited investment by pharmaceutical companies in new antibiotics has curtailed the clinical efficacy of available antibiotics (37,38). The risk of developing side effects, such as allergy or antibiotic resistance, has resulted in recommendations stating that it is contraindicated to use topical antibiotics for the treatment of non-healing wounds (39).

Antiseptics

The emergence of microbes with reduced susceptibility to antiseptics is a continuing problem (40–42).

Both antibiotic and antiseptic resistance mechanisms can be caused by a reduction of cellular influx and the higher activity of efflux pumps, blocking entrance and increasing drug excretion, respectively (42–46). The prevalence of organisms with cross-resistance to antibiotics and antiseptics has also been recognised (47–50). Bacteria have an innate defence against toxic compounds via the up-regulation of multidrug efflux pumps. These include *qacA* in *S. aureus* and *mexAB-oprM* in *P. aeruginosa*. Once expressed, these efflux pumps are fairly indiscriminate and will not only excrete antiseptics, but also antibiotics and heavy metals. Expression of the efflux pumps can therefore result in multidrug resistance (51). It therefore seems important not only to optimise antibiotic use, but also to monitor and even restrict the use of antiseptics in the healthcare environment (42,52–54).

3.2 Indications for treatment

To prevent infection

Guidelines on diabetic foot infection published by the International Working Group on the Diabetic Foot (IWGDF) suggest how and when to treat diabetic foot infections and how to manage wounds (55–57). Other features (or secondary) signs suggestive of infection include the presence of necrosis, abnormal coloration, friable granulation tissue, non-purulent secretions and fetid odour. Such secondary signs might be helpful when inflammation is absent (e.g., in some cases of neuropathy or ischemia). The limited available evidence does not support the use of systemic antibiotics for treating clinically uninfected wounds in the diabetic foot, to either enhance healing or prevent clinical infection (56,58). There is no compelling evidence to support that the presence of many bacteria hampers wound healing (59,60).

A Cochrane review of honey-based dressings in all wound types was published in 2015 (61) and concluded, as did the 2020 IWGDF guidelines (56,58), that relative to its comparators, honey had an unclear effect on healing. It suggested that health services should avoid the routine use of honey dressings until sufficient evidence of effect is available (56,58).

In summary, there is little new evidence to support the use of antibiotic or antiseptic topical treatments to prevent wound infection, or to promote the healing of chronic ulcers (55,56,58–62).

Resolution of infection

There is a limited number of comparative studies of resolution of infection as an endpoint, and these are predominantly in the diabetic foot. In the previously mentioned 2020 systematic review, there were 25 controlled studies of (systemic) diabetic foot infections (56). One publication on the use of a topical antibacterial peptide, compared with oral antibiotics in mildly infected DFUs, showed it resulted in comparable outcomes with fewer side effects (55). Unfortunately, antibacterial peptides like these are not currently available in clinical prac-

tice. The systematic review also identified studies of topical antimicrobial treatment of diabetic foot infections (including one Cochrane systematic review)(29). Three small randomised controlled trials (RCTs) compared topical treatments of superoxidised water with other topical antiseptics or systemic antibiotics in (post-surgical) diabetic foot wounds (63–65), one of topical iodophor application compared with either acrinol or a control group. Although there were some differences in outcomes, it was not possible to draw conclusions from these studies because of potential bias; incomplete reporting; underpowered study designs; or a lack of reported outcomes on wound healing, infection occurrence or the resolution of infection. The previously mentioned 2017 Cochrane review of antimicrobial dressings in DFUs pooled several studies of antimicrobial dressings (29). These antimicrobials included products with various forms of silver (silver sulfadiazine, silver ion dressing/ionic silver, silver nitrate, silver oxide, silver collagen), various forms of iodides (cadexomer, povidone and compound/tincture), superoxidised water, zinc, silver sulphadiazine, tretoinin, pexiganan cream and chloramine. The authors concluded that the quality of the studies was low, which made it hard to draw conclusions. There was low-certainty evidence that the use of an antimicrobial dressing instead of a non-antimicrobial dressing might increase the number of DFUs healed over a medium-term follow-up period. Also, there is moderate-certainty evidence that there is little difference in the risk of adverse events related to treatment between systemic antibiotics and topical antimicrobial treatments (29).

Another Cochrane review of the topical treatment of facial burns identified only two studies using topical antimicrobial dressings with silver sulphadiazine or sodium carboxymethylcellulose silver (66). The application of silver in a dressing was found to make little or no difference in the proportion of healed wounds (with low certainty evidence), or in the resolution of wound infection (with very low certainty evidence).

Strengths and limitations of the current evidence base

Much can be gained from reporting study results in a standardised fashion, such as those offered by the IWGDF and CONSORT standards (67,68). The development of tests and techniques to improve tissue sampling and analysis, imaging technology and scientific progress in cellular and molecular biology has enabled the development of more 'objective' wound outcome parameters for assessing both the wound condition and the treatment intervention. However, tests that use physiological changes and molecular biology to assess wound healing are still not widely used outside pre-clinical research settings. The challenge, especially with regard to non-healing wounds, is still that objective endpoints (preferably assessed by an independent observer) are difficult to achieve. Some controversy concerning how to measure infection remains: should it be by the examination of clinical signs and symptoms, by microbiological methods, by laboratory parameters indicating inflammation or by a combination of these parameters (68)? Different wound classification systems have been suggested for assessing clinical infections, primarily relating to acute skin infection, acute surgical infection and chronic diabetic foot infections. The updated IWGDF classification (55) and the closely related Wifl classification (69) are more widely used to assess the severity of DFU infection, the LRINEC score for necrotising soft tissue infection (70), the USC (71), the DUSS and MAID and the DFI for other wounds (72–75).

3.3 Questions covered in 2013 & updated statements

In this section, we have included key questions concerning the treatment of wound infections from the 2013 document (11) for which there are new findings leading to adjustments of the statements provided in the original document.

Q1: Do we have clinical data which demonstrates that the use of topical antimicrobial

treatments prevents reinfection in non-healing wounds?

There are limited clinical data to support that the use of topical antibiotic or antiseptic treatments can prevent the recurrence of infection. To our knowledge, there are no new clinical data to support that the use of antiseptic treatments can prevent recurrence of infection.

What type of evidence should we be looking for?

Q2: Should wound dressings and antimicrobial agents be tested only against planktonic bacteria?

We believe that, if biofilms inhibit wound healing, antiseptic and topical (and systemic) antibiotic treatments should be tested against them in future clinical studies (see Section 2.1).

It could be argued that the reason why so many dressings and antimicrobial agents fail to eradicate bacteria from non-healing wounds and other chronic infections is that they were designed only for planktonic bacteria. Susceptibility testing of sessile bacteria in biofilms is not widely available in clinical microbiology laboratories – only in research settings. In the future, however, it will be important to assess the efficacy of antimicrobials in bacteria in biofilm, as new drugs and devices are developed to fight bacteria in biofilms.

Q3: What endpoints do we need to justify the use of topical and local antimicrobial treatments in non-healing wounds?

To justify the use of topical and local antimicrobial treatments in non-healing wounds, we propose that studies primarily use the endpoints of either prevention or the resolution of infection. The use of increased healing rates or shorter healing times as primary endpoints is also valid, but the study must then be adequately designed so the correlation between the antimicrobial intervention and outcome can be validated. As infection should be

defined clinically, and the number of bacteria in wounds has no clear relation with infection, the use of bacterial quantification (e.g., 'reduction of bioburden') or the achievement of sterility to define resolution of infection is not useful. Other factors that can play a role in wound healing should be controlled for if wound healing parameters are used as endpoints (e.g., limb ischemia, biomechanical pressure, venostasis and local necrosis).

Infection as endpoint

Q4: Can resolution of infection be used as an endpoint in wound healing studies?

We think that resolution of wound infection is a valid endpoint in a wound healing study and that clinical parameters should be used for the definition of wound infection.

Resolution of infection is a clinically important factor for healing and could be a valuable endpoint in an RCT. As mentioned, the commonly used endpoints of wound closure, healing rate, time to complete, epithelialisation, quality of life and wound environment are all only, to some extent, dependent on the presence of infection.

The critical point is how infection should be evaluated. It is most often defined by the presence of clinical signs and symptoms. It is, unfortunately, not always possible to rely entirely on clinical signs and symptoms of infection, due to the lack of visible responses of the innate immune system (e.g., in case of ischemia, neurological dysfunction or an immunocompromised state, see Section 3.2). Several updated infection classifications based on the presence of clinical signs and symptoms, sometimes combined with laboratory parameters, are currently available to assist in assessing the presence of wound infection. There is no evidence that one classification or wound score is better than another. Decisions on a local or systemic treatment, or a combination of these treatments, must follow the diagnosis of infection.

Strengths and limitations of the current evidence base

Q5: What are the controversies regarding the methodology of studies providing evidence for topical antimicrobial treatment?

There is a lack of agreement among clinicians regarding the conduct of research in wound management. Generating a strong evidence base is fraught with methodological challenges.

RCTs are still considered the reference standard in evidence-based healthcare for conducting clinical trials (76); however, because clinicians need to know how the products will work on their cohort of patients, other types of (non-controlled) study designs may also be relevant. Clinical studies in wound care are often hampered by inadequate sample sizes and cohort variability, non-blinded outcome assessments and inadequate follow-up, and a lack of clear descriptions of interventions is often present in wound care research (67,68). Although guidelines have been published in an attempt to standardise research conduct and reporting, there seems to be lack of agreement in research on wound management (77). For researchers, this makes funding for clinical research challenging, and for clinicians it diminishes the availability of the different treatment options due to conflicting results. It is important, however, to highlight that a lack of evidence of efficacy is not the same as evidence of inefficacy.

3.4 Overall conclusions & implications for clinical practice

Based on the findings in this section, we conclude that:

- Little clinical data supports that the use of topical antibiotic or antiseptic treatments can prevent the occurrence or recurrence of infection

- Already available tests should be adopted clinically for antimicrobial effects on micro-organisms in a biofilm (sessile) phenotype and for those in the planktonic phenotype
- Studies on the value of topical antimicrobial treatment for wounds should have either prevention of clinical infection or clinical resolution of infection as the primary endpoint
- The use of wound healing as one type of primary endpoint is acceptable, but the study must be adequately designed so the correlation between the antimicrobial intervention and outcome can be validated
- Resolution of a wound infection is a valid primary endpoint
- Wound infection should be defined by the presence of clinical signs and symptoms of inflammation and may be supported by various laboratory parameters
- Researchers should adhere to standard research guidelines to support improved uniformity and comparability of clinical studies

4. The patient perspective

Sebastian Probst

4.1 Introduction

Currently there is a growing interest in understanding an individual's perspectives on their own treatment and care. The 'patient perspective' is defined as the individual's experience of living with a non-healing wound and its impact on him/her, including the physical, psychosocial and goal-oriented dimensions of the disease and its treatment. Asking not only what an individual wants or needs, but also what they value, results in more meaningful decision-making for both preventive and responsive wound care. This chapter summarises the main points from the 2013 document on the patient perspective, provides an overview of where we are now and discusses how clinical practice and research could proceed.

4.2 The clinical needs of individuals with non-healing wounds

Every individual with a non-healing wound should expect to have access to treatment that is timely, appropriate, person-centred and of the highest quality. A lack of appropriate attention to the clinical needs of the patient can lead to an increased risk of bioburden. Evidence demonstrates that patients expect that healthcare professionals inform them not only about the most accurate, but also about non-standard, treatment options (78). In dealing with wounds with a problematic bioburden, accurate and on-going assessment should be done to ensure correct identification of the patient's clinical needs, to employ the most appropriate interventions. Nevertheless, with the rising threat of antibiotic resistance, antibiotics should only be used when necessary. To positively

influence clinical outcomes, the patient should be included in all decisions when possible.

Safety of patients with wounds

Patient safety aims to ensure the prevention of errors and adverse effects to healthcare patients. Often, the relationship between wound infection and patient safety is not clearly appreciated. Nevertheless, the link between the quality of healthcare services and the prevalence of nosocomial infections and care-induced lesions in patients with wounds is clearly demonstrated (79). Nosocomial infections contribute to increasing morbidity, mortality and excessive healthcare costs. Patients' confidence in the capacity of health services is consequently reduced. Correct patient and wound assessment might sometimes be challenging, making the choice of treatment difficult. In an attempt to manage bioburden, clinicians may often overuse antimicrobials (80). This tendency is exacerbated by a perceived demand from patients on physicians to prescribe antimicrobials, particularly antibiotics (81). On the other hand, insufficient treatment of infected wounds might compromise the health and well-being of the individual (82).

Patient involvement

Patients with non-healing wounds need a plan of care that often continues over months, years or even a lifetime. Patients and their families should receive information on how to manage a wound, be involved in decision-making and be satisfied with the care they receive (83). However, patients and their families often receive too little support, information and advice from health professionals, and are not well integrated into the planning of wound care interventions (84). Thus, nurses and physicians need skills to empower patients and their families. Patients often believe that antibi-

otics are needed and can persuade the physician to prescribe them. If a reduction in the use of antimicrobials is to be achieved, it demands the involvement of patients and their families as equal partners in the decision-making and care process, as well as access to ongoing education and self-management support according to their capabilities.

4.3 Questions covered in 2013 & updated statements

In this section, we cover the key questions concerning the patient perspective on antimicrobial treatment of wound infection from the 2013 document (11) for which there are new findings leading to adjustments of the statements provided in the original document.

Q1: Is the link between inappropriate management of individuals with wounds and patient safety clearly appreciated?

Judicious use of antiseptic products and antibiotic therapy is key to delivering safe and effective patient care, and to limiting the emergence of drug-resistant organisms. Education and training for both patients and clinicians, implementing integrated standards of care, ensuring good communication and teamwork are all essential to ensure the appropriate use of antimicrobials. This, in turn, will aid in achieving a robust patient safety culture within healthcare services that will drive enhanced clinical outcomes.

Q2: Does the insufficient application of agreed-upon standards of care for infection in non-healing wounds impact patient outcomes?

Symptoms and signs caused by wound infection, such as pain, odour and purulent exudate, have a great impact on the quality of life of both patients and their relatives. These symptoms are associated with anxiety, reduced social interactions and increased dependence on others, which in turn may interfere with healing. While drainage from

wounds may be managed by frequent dressing changes, wound odour is difficult to hide. For managing wound odour, professionals generally rank treatment with antiseptics as most efficacious (85); however, there is sparse data on which antimicrobials, given by which route and for how long are most appropriate. Furthermore, there is little published information on the safety of using various antimicrobials in managing wound odour, so they are often not used (86).

Q3: Are patients considered equal partners in planning wound care interventions?

We believe that achieving a reduction of the inappropriate use of antimicrobials for the management of wounds requires the involvement of not only healthcare personnel, but also the empowerment of affected patients and their families. This may be achieved through the efforts of a properly constructed interdisciplinary wound care team. Nurses, physicians, pharmacists and other members of the team need skills to care for and teach patients, as well sufficient designated time to assess and manage these complex patients.

4.4 Overall conclusions & implications for clinical practice

Evidence demonstrates that including patients in the decision-making process about their care can enhance their motivation and knowledge (87). The need for patient involvement may change over the trajectory of their illness, being influenced by factors such as the patient's age, the duration of their wound, their underlying diseases, their level of education and literacy. Healthcare professionals must therefore explore each patient's perspective to gain insights on the complex issues that impact their individual patient's life. Providing proactive wound management while including the patient perspective may improve the wound outcomes and encourage the patient to engage as an active partner in his/her management. More research is needed concerning these various aspects of involving patients and their families in the care of their wounds.

For clinical practice, these conclusions point to the following recommendations:

- Healthcare providers should strive to involve patients and their families in wound care.
- Correctly assessing the presence, type, severity, and microbial cause of infection in a wound is key to identifying the appropriate and judicious use of antimicrobial products in their management.
- Educating and empowering patients and their families about managing the wound will likely lead to better clinical outcomes and patient satisfaction.

5. Economics & organisation of care

Jan Apelqvist

5.1 Introduction: the burden of non-healing wounds

In 2013 (11), we described how non-healing wounds are associated with long recovery duration and a high incidence of complications, most frequently infection, resulting in a considerable financial burden both from a societal perspective and from the perspective of the healthcare providers. These costs are estimated to account for up to 2–4% of the healthcare budget, with an expected substantial underestimation due to a lack of adequate data from many countries and an increasing elderly and diabetic population.

Recent data are provided in a retrospective cohort analysis of the electronic records of patients with wounds managed by the UK's National Health Service (NHS) in 2017/2018 (88). In this analysis, the resource use and costs of primary and secondary care sectors in the UK were evaluated. According to this study, there were an estimated 3.8 million patients with a wound managed by the NHS in 2017/2018. Annual levels of resource use attributable to wound management included 54.4 million district/community nurse visits, 53.6 million healthcare assistant visits and 28.1 million practice nurse visits. The annual NHS cost of wound management was £8.3 billion; 81% of the total annual NHS costs were incurred in the community; and 78% of patients with DFUs and 41% of individuals with venous leg ulcers (VLU) had a recorded infection. The annual prevalence of wounds increased by 71% between 2012/2013 and 2017/2018. There was a substantial increase in resource use over this period, and patient man-

agement costs increased by 48% in real terms. Corresponding data have been presented in various countries/regions in the Western world and been related to an increasing elderly population, increased prevalence of diabetes and individuals with multiple organ diseases (89–97). For wound type-specific costs and considerations, please see the 2013 EWMA Document (11).

The high prevalence of infection in DFU and the accompanying economic burden was also described in the 2013 document (11). Since then, several studies and reviews have been presented concerning the need for effective DFU interventions, but few have been subject to a full economic evaluation (89,91,92,94–114). All interventions examined in these evaluations were cost-effective or cost-saving in a clinical situation involving DFU infection. Collectively, they suggested that the short- and long-term implementation of such interventions could reduce the burden of DFU infections on healthcare systems while still providing optimal patient management. Although the evaluations captured the standard care for DFUs and associated costs, other concerns arose related to the issue. These included assessments of antibiotic efficacy, the route and setting of administration and the overall strategies embodied. However, as illustrated in a systematic review of diabetes-related foot infections, most studies included in the final analysis were too heterogeneous to allow comparison. This conclusion is in agreement with a 2018 EWMA document about advanced therapies in wound management (115), which pointed to the scarcity and limited robustness of the available economic studies on advanced therapies in wound management. A corresponding conclusion was made in a systematic review regarding VLU

(116). Based on these publications, we conclude that there is an increased economic focus on wound management, particularly with regards to infection, but there is a substantial need for more robust studies (117).

However, these data remain difficult to obtain in many countries and in the various relevant healthcare organisations for several reasons (95,118,119):

- Lack of adequate population-based data
- Patients are treated by different healthcare professionals/disciplines and at varying levels of care (e.g., inpatient/outpatient, primary care, home care, or patient self-care/private care)
- Patients who are not followed to a specific endpoint
- Differences in resources used or available
- Different treatment strategies
- The influence of different reimbursement systems
- The economic cost/price of the product or procedure used varies across countries, regions and depending on whether it is reimbursed or not and who is the payer

It can still be concluded that non-healing wounds often result in a considerable financial burden, associated with long healing times and a high incidence of complications. When evaluating the consequences of a wound infection, it is therefore essential to view the consequences as an integrated part of the total management and resource utilisation of an individual with a non-healing wound (11).

5.2 Questions covered in 2013 & updated statements

It is important to be aware of costs associated with the non-optimal management of complex wounds, particularly in cases with cross-sectional care. The economic impact of the organisation of care and the danger of fragmented care due to the lack of coordination between various disciplines and levels of care, has been illustrated in reports with regard to the management of complex wounds, particularly DFUs (120–122)(123–126). A substantial number of studies indicate the importance of organisation in wound care, as well as the interdisciplinary coordination of treatment strategies to achieve optimal care with regard to both outcome and cost (127).

The following questions were answered in the 2013 document Antimicrobials and Non-Healing Wounds (11).

- What is the cost effectiveness of antiseptic versus antibiotic treatment (not just prices of products, but also societal costs)?
- Is it cheaper to amputate limbs of an individual with an infected wound than to treat (conservatively) with antibiotics?
- Do restrictions on the use of products due to their price have consequences, and what are these consequences?

As no new conclusions have been presented since 2013, these questions are not repeated in this update, but can be found in the document published in 2013 (11).

In this updated paper, we do, however, find it important to highlight the importance of recognising the perspective of each of the relevant decision-makers when an economic analysis is performed. In wound care, decision-makers include clinicians, hospitals or other healthcare provider organisations and third-party payers. For example, from a hospital-management perspective, the cost of intravenous antibiotics or revascularisation could be considered high, particularly because it might

prolong the length of the in-hospital stay. However, from a societal perspective, the use of antibiotics and revascularisation in this case is only a fraction of the total cost spent to achieve complete wound healing.

5.3 Overall conclusions & implications for clinical practice

Concerning the economics and organisation of care, in relation to the management of wound infections, we conclude the following:

- If cost and resource-use studies are lacking, clinicians lack the robust economic arguments and strong outcome data that they must present to fundholders in order to support the implementation of the most cost-effective treatments and care strategies for infected wounds.
- Infection is the most frequently occurring complication in non-healing wounds. When evaluating the consequences of a wound infection, it is essential to see its management and outcome as an integrated part of the total management and resource utilization of an individual with a non-healing wound. It is important to identify interventions and strategies early, to avoid complications and facilitate healing, and in terms of cost implications.
- It is essential to be able to understand and use health economics as a valuable tool in clinical practice for developing efficient treatment strategies for the prevention and treatment of individuals with wounds.

6. Future perspectives & antimicrobial stewardship

Karen Ousey and Benjamin A. Lipsky

6.1 Introduction

Much discussion and many papers have addressed the continued increasing global threat of AMR (128–130). Increasing resistance of microorganisms to antimicrobials is predicted to be associated with up to 10 million deaths annually by 2050, exceeding deaths associated with cancer (131). The increasing use of antibiotics in recent decades has led to selection pressure that encourages antibiotic-resistant strains to emerge and increase in prevalence (131). Judicious use of all antimicrobial agents is urgently needed to retain effective methods for treating and preventing infections, thus avoiding a return to the constraints (e.g., in surgical procedures or immunocompromising therapy) that characterised the pre-antibiotic era (12).

All open wounds are contaminated or colonised with microorganisms, but not all contaminated wounds become infected. As wound infections are associated with considerable morbidity, occasional mortality and substantial financial expense, it is incumbent upon all healthcare providers to make efforts to prevent them. As noted by the International Wound Infection Institute's (IWII) 2022 guideline *Wound infection in clinical practice* (132), the likelihood of a wound becoming infected is related to characteristics of the individual (systemic and multifactorial host factors), their wound and the environment. Prevention of wound infection is focused on implementing strategies to reduce the patient's individual risk factors (8,9,133).

A key approach to reducing the problems of AMR

and wound infection is following the principles of antimicrobial stewardship (AMS). AMS refers to the supervised and organised use of antimicrobial agents (132). In healthcare, this refers to a coordinated programme designed to decrease the spread of infections caused by multidrug-resistant organisms and improve clinical outcomes by encouraging appropriate and optimised use of all antimicrobials (134). In brief, these include: avoiding prescribing antimicrobials unless they are necessary, prescribing as narrow a spectrum of antimicrobial therapy as required, choosing the most appropriate route of therapy and limiting the duration of treatment to the shortest time necessary (135). Several authoritative organisations have emphasised the need for implementing AMS principles (12). The 2013 EWMA document identified ensuring prudent use of antimicrobial agents as an area requiring urgent action. The continuing increase in the prevalence and costs of wound infections (93,136,137), and the persistent problems in developing new antibiotics (138), necessitate novel approaches to optimising and conserving current interventions aimed at preventing infection (139). A recent paper in *The Lancet* using predictive statistical modelling approximated that, in 2019, there were 4.95 million global deaths associated with, and 1.27 million deaths directly attributable to, bacterial AMR (6).

While much of the focus of AMS is on systemic antibiotic agents, judicious use of topical antiseptics also plays a role in preventing and managing wound infection (22). This begins with only using these agents to treat clinically infected wounds and moves to limiting the duration of treatment based on the findings of regular wound assessments (22,29,132,140,141). Selection of topical

antimicrobial treatment should also consider the following (132,140):

- Antimicrobial action of known efficacy for likely or confirmed pathogens
- Broad-spectrum agents only when likely polymicrobial pathogens or unpredictable sensitivities
- Known or likely efficacy in achieving clinical goals of care of the individual
- Minimal cytotoxicity, irritancy and allergenicity to wound tissue and peri-wound skin
- Fast acting (when severe infection); long acting (when patient adherence is a problem)
- Low propensity to select for AMR
- Local availability of agents and guidance for their use

Topical antimicrobials play a role in treating the wound when it is likely to be clinically infected or confirmed as containing biofilm. There is no clear evidence that treatment with topical antimicrobials can prevent wounds from becoming infected, but in those at high risk (e.g. occurring in immunocompromised or post-high risk surgery patients), prudent use may be appropriate (29,141).

In wound care, early identification of infection is an integral part of AMS programmes, as its eradication helps avoid non-healing. Key AMS strategies include (12,142): promoting known effective infection control methods such as hand hygiene practices; creating and a continually updating a local, evidence-based AMS knowledge base; ensuring educational opportunities for clinicians about the appropriate use of antimicrobials; auditing actual antimicrobial treatments to identify and correct inappropriate practices related to decisions to treat; the selection of empirical and definitive regimens, route and dose of therapy; and the duration of therapy. The main goals are to only treat clinically

infected (not uninfected) wounds, using the narrowest spectrum antimicrobial regimen at the lowest required doses, for the shortest required duration. This effort should be supported through the development and incorporation of infrastructure that allows clinicians to diagnose infection accurately, and to rapidly institute appropriate antimicrobial treatment (135,143).

Numerous global initiatives have been created to measure the effects of programmes developed to tackle AMR, including:

- 2014 Transatlantic Taskforce on Antimicrobial Resistance (TATFAR)(144)
- Global Antibiotic Resistance Partnership (GARP)(145)
- Global Health Security Agenda (GHSA)(146)
- Global Action Plan on Antimicrobial Resistance (130)
- The UK's five-year national action plan (129)
- The Tripartite Partnership among the Food and Agriculture Organization of the United Nations (FAO), the World Health Organization (WHO) and the World Organisation for Animal Health (OIE)(147)
- World Antimicrobial Awareness Week, coordinated annual by the WHO (148)

Many factors contribute to the misuse of antimicrobials. Key issues identified by the WHO include: clinicians' fears related to diagnostic uncertainty; limited clinical skills and knowledge; litigation anxiety associated with withholding or constraining antibiotic therapy; and failure to properly follow available clinical guidelines (149). Furthermore, healthcare workers with heavy workloads often lack time both to fully evaluate the cause and appropriate management of an infection, and to take advantage of opportunities to update their knowledge. Management strategies for wound in-

fection must be properly targeted and provided in a timely, efficient, evidence-based manner, preferably by a multi-professional team. Adopting such a systematic approach should help reduce the adverse outcomes that so often occur with wound infections (12). Indeed, a study in Sweden (149) demonstrated the potential for improved wound management using a national quality registry for structured ulcer care. The project data revealed an immediate effect of their Registry of Ulcer Treatment within wound management in significantly reducing healing time from 146 days (21 weeks) in 2009 to 63 days (9 weeks) in 2012. They also noted a reduction of antibiotic treatment from 71% before registration to 29% between registration and ulcer healing (149).

While antimicrobial therapy is a key component of treating infected wounds, optimal management also involves cleansing and debriding the wound and selecting appropriate dressings, devices (e.g., for pressure offloading), vascular assessment and optimised nutrition. Other broader and pragmatic issues to consider include various administrative, psychological and social factors that may interfere with the wound healing process.

6.2 Questions & statements

As antimicrobial stewardship was not specifically discussed in the original version of this document (11), we have added the following questions to this update to highlight the aims of this approach and provide guidance on the appropriate use of antimicrobials in wound management.

Q1. Which types of antimicrobial agents should clinicians choose to treat wound infections, while minimising the risk of AMR?

Before deciding which antimicrobial to use, it is essential to assess whether to use any, as these agents are generally reserved for managing clinically infected wounds. Infection of a wound is defined by the presence of at least two of the classical (inflammatory), or possibly secondary, signs or symptoms of inflammation. For infected wounds,

there are a range of topical and systemic antimicrobial products available. Clinicians should consider the most appropriate class of agent, route of therapy, spectrum of activity required and duration of therapy. For optimal definitive therapy, clinicians should obtain appropriate material (tissue, rather than swabs) for culture and sensitivity testing and then seek guidance from local and national policies and guidelines. When in doubt, clinicians should seek input from experts, including (when available) an interdisciplinary team. For additional information relating to the identification of wound infection, we refer to the IWII 2022 Wound Infection in Clinical Practice document (132).

Q2. Should antimicrobials be used to prevent an infection?

Uninfected wounds generally do not require antimicrobial therapy; no high-quality data demonstrate that administering antimicrobials either prevents wound infection or accelerates wound healing. Numerous studies have documented there is an excessive use of antibiotics to treat patients with uninfected but non-healing wounds.

An essential practice for both treating and preventing wound infection is wound bed preparation. Any tissue that is suspected of being devitalised or colonised by biofilm requires vigorous therapeutic cleansing of microorganisms and detritus from the wound bed. Rigorous therapeutic cleansing of chronic or hard-to-heal wounds and is performed: to remove excessive wound exudate or debris from the wound bed to optimise visualisation and assessment; prior to collection of a wound sample (swab or biopsy) to reduce contamination; and to assist in hydrating a desiccated wound bed (150).

Antimicrobials (most often antiseptics) may be indicated for selected patients or types of wounds that are at high risk of infection. This might be treating in conjunction with extensive surgical debridement as a component of biofilm-based wound care (151), to help prevent infection in high risk (e.g. contaminated) surgery, or when the consequences of infection are serious (e.g.

An antimicrobial strategy for non-healing wounds should include:

- *Routinely determining if the wound is infected*
- *Surveillance programmes for wound infection*
- *Clear and achievable metrics*
- *Local policies to review the appropriateness of antimicrobial use*
- *Accessible multi-professional educational programmes*
- *Antimicrobial guardianship programmes*
- *Patient awareness campaigns*

Table 1: Antimicrobial strategy for non-healing wounds

cardiac valve surgery)(152). IWII 2022 also states there is a role for judicious wound irrigation with an antiseptic solution in selected circumstances. Both healthcare professionals and their patients should be educated on the clinical and financial benefits of not using the precious and limited resource that antibiotics represent for uninfected wounds. A strong infection control programme, in collaboration with AMS guardians, can provide useful advice and education.

6.3 Overall conclusions

This section is aimed at briefly exploring the value of antimicrobial stewardship programmes and highlight actions needed from various key stakeholders to help achieve the goals for the appropriate use of antimicrobials in wound management. AMR is undoubtedly among the gravest global threats to clinical medicine, but we now have methods to reduce its occurrence and improve outcomes in treating wounds. We hope that readers will be both chastened by the crisis and heartened by the role they can play in reducing the risk and improving outcomes in patients with wounds.

Setting/field	Action	Difficulties
Research community & industry	Areas of active research include those related to: management of biofilm and the use of new techniques (e.g. infrared and digital imaging) in the early diagnosis of wound infection; standardisation of methods to evaluate the effectiveness of antimicrobial dressings against both planktonic and biofilm bacteria and microbial communities associated with wounds	<p>Collecting comparable data from different sites</p> <p>Limited available research in various aspects of biofilms</p> <p>Lack of equity and global guidance for the use of new technologies</p> <p>Limited prospective, cohort and comparative (especially randomised controlled) studies of these issues, as well as of the role of antimicrobial treatments for clinically uninfected non-healing wounds</p>
Clinical practice/ healthcare organisations/ payers	<p>Develop wound-specific AMR education programmes</p> <p>Ensure all healthcare professionals are aware of AMS principles</p> <p>Implement established AMS pathways</p> <p>Implement available AMS guardian programmes</p>	<p>Lack of data on the appropriate use of antimicrobials in wound care</p> <p>Lack of data to support specific recommendations</p> <p>Variations in costs for, and organisation of, wound care across settings/ countries</p> <p>Frequent unrestricted use of antibiotics, and a lack of national pharmaceutical policies to coordinate surveillance, regulation and education</p>
Payers	Motivate reimbursement systems to implement effective wound care strategies in both in- and out-patient settings to promote the appropriate use of antimicrobials	Variations in funding and recording methods impair identifying reasons for, and duration of, prescribed antimicrobial therapies

Table 2: Future perspectives for research, clinical practice and payers

7. A concise approach to treating potentially infected wounds

This updated algorithm (11), with recommendations on routes of treatment with antimicrobials in accordance with stewardship principles, is aimed

at providing concise guidance for clinical practitioners in implementing our key messages.




Figure 2: Algorithm on when to treat/not to treat with antibiotics and antiseptics

8. Conclusion

This update document on Antimicrobials and Non-healing Wounds provides support for clinical decision-making using the latest evidence for an appropriate use of antibiotics and antiseptics in wound management. AMR is a global problem in clinical practice, even though methods to reduce the occurrence of antimicrobials and improve outcomes when caring for wound patients exist. Wound infection is one of the most frequently occurring complications in non-healing wounds. The presence of infection can be established via clinical signs and symptoms of inflammation that may be supported by various laboratory parameters. Towards this end, healthcare professionals must have the knowledge and skills to evaluate wound infection and knowing the consequences of different routes of treatment. Antimicrobial stewardship must be seen as an integrated part of the total management and resource utilization of an individual with a non-healing wound. While it is important to identify interventions and strategies early to avoid complications and facilitate healing, these also often have cost implications. Preventing, managing and treating wound infection in clinical

practice ideally involves not only antibiotics and antimicrobials, but also an understanding of the individual patient's perspective on how an infection impacts their life. Providing proactive wound management while including the patient perspective is necessary to improve the wound outcomes and encourage the patient to engage as an active partner in his/her treatment.

Clinical practice, however, shows that there is still a lack of knowledge, especially about the role of biofilms in non-healing wounds, with a tendency to adopt an in vitro-based model for how bacteria grow in non-healing wounds. Taking into consideration the latest evidence on the value of topical antimicrobial treatment for wound care, the primary endpoint should be defined either as the prevention of clinical infection, clinical resolution of infection or resolution of a wound infection. It is therefore recommended that researchers adhere to standard research guidelines to support improved uniformity and comparability of clinical studies.

9. Glossary

Term	Definition
Antibiotic	<p>A chemical substance that either kills or inhibits the growth of a microorganism, such as bacteria, fungi or protozoa, and which can be used both topically and systemically. Antibiotics have three major sources of origin: (i) naturally isolated, (ii) chemically synthesised or (iii) semi-synthetically derived. They can be classified according to their effect on bacteria—those that kill bacteria are bactericidal, while those that inhibit the growth of bacteria are bacteriostatic. Antibiotics are defined according to their mechanism for targeting and identifying microorganisms—broad-spectrum antibiotics are active against a wide range of microorganisms; narrow-spectrum antibiotics target a specific group of microorganisms by interfering with a metabolic process specific to those particular organisms (153).</p>
Antimicrobial	<p>The term ‘antimicrobial’ is an umbrella term and refers to disinfectants, antiseptics (sometimes referred to as skin disinfectants), antivirals, antifungals, antiparasitics and antibiotics (132).</p>
Antimicrobial resistance	<p>The ability of a microorganism to survive and even replicate during a course of treatment with a specific antibiotic or antiseptic. It can arise from gene acquisition and/or mutation. Failure to resolve an infection with the first course of an antibiotic or antiseptic treatment may mean that the infection spreads or becomes more severe.</p> <p>Intrinsic resistance: Bacteria have never been shown to be susceptible.</p> <p>Acquired resistance: Previously susceptible bacteria have become resistant as a result of adaptation through genetic change.</p> <p>Multidrug resistance: Corresponds to resistance of a bacterium to multiple antibiotics (153).</p>
Antimicrobial tolerance	<p>Tolerance is distinct from resistance, since resistance is caused by the acquisition of determinants that regulate active mechanisms, which directly diminish the action of the antimicrobial agent and allow cell division and microbial growth, whereas tolerance enables the cells in biofilms to sustain longterm exposure to the antimicrobial agents without loss of viability or genetic change. Antimicrobial tolerance is not due to a permanent genetic change (18).</p>

Term	Definition
Antiseptic	An antiseptic is a topical agent with broad spectrum activity that inhibits the multiplication of, or sometimes kills, microorganisms. Depending upon its concentration, an antiseptic may have a toxic effect on human cells (132).
Bacteria	Prokaryotes can be divided into categories, according to several criteria. One means of classifying bacteria uses staining to divide most bacteria into two groups (Gram-positive, Gram-negative), according to the properties of their cell walls (153).
Bioburden	Bioburden is the population of viable microorganisms on/in a product, or on a surface (154).
Biofilm	A coherent cluster of bacterial cells imbedded in a biopolymer matrix, which, compared with planktonic cells, shows increased tolerance to antimicrobials and resists the antimicrobial properties of host defence (18).
Host defence	The capacity of an organism or a tissue to withstand the effects of a harmful environmental agent (18).
Non-healing wounds	Wounds that fail to progress through an orderly and timely sequence of repair. Also referred to as chronic, complex and hard to heal wounds (11).
Reduction of bioburden	Reduction of the size and diversity of a microbial population (154).
Wound infection	<p>When the quantity of microorganisms in a wound becomes imbalanced such that the host response is overwhelmed and wound healing becomes impaired. Transition from non-infected to infected is a gradual process determined by the quantity and virulence of microbial burden and the individual's immune response (132).</p> <p>Signs and symptoms of inflammation caused by tissue invasion of micro-organisms define the presence of wound infection.</p>

10. References

- Martinengo L, Olsson M, Bajpai R, Soljak M, Upton Z, Schmidtchen A, et al. Prevalence of chronic wounds in the general population: systematic review and meta-analysis of observational studies. *Ann Epidemiol*. 2019 Jan;29:8–15.
- Gethin G, Touriary E, van Netten J, Sobotka L, Probst S. The impact of patient health and lifestyle factors on wound healing, Part 1: Stress, sleep, smoking, alcohol, common medications and illicit drug use. *J Wound Manag*. 2022;23(1 Pt 1):1–41.
- Gould L, Abadir P, Brem H, Carter M, Conner-Kerr T, Davidson J, et al. Chronic Wound Repair and Healing in Older Adults: Current Status and Future Research. *J Am Geriatr Soc*. 2015 Mar;63(3):427–38.
- Olsson M, Järbrink K, Divakar U, Bajpai R, Upton Z, Schmidtchen A, et al. The humanistic and economic burden of chronic wounds: A systematic review: The burden of chronic wounds. *Wound Repair Regen*. 2019 Jan;27(1):114–25.
- Bessa LJ, Fazii P, Di Giulio M, Cellini L. Bacterial isolates from infected wounds and their antibiotic susceptibility pattern: Some remarks about wound infection: Bacterial isolates from infected wounds and their antibiotic susceptibility pattern. *Int Wound J*. 2015 Feb;12(1):47–52.
- Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. *The Lancet*. 2022 Feb;399(10325):629–55.
- World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) report: 2021 [Internet]. Geneva: World Health Organization; 2021 [cited 2022 Apr 12]. Available from: <https://apps.who.int/iris/handle/10665/341666>
- Siddiqui AR, Bernstein JM. Chronic wound infection: Facts and controversies. *Clin Dermatol*. 2010 Sep;28(5):519–26.
- Edwards-Jones V. Antimicrobial stewardship in wound care. *Br J Nurs*. 2020 Aug 13;29(15):S10–6.
- Guan H, Dong W, Lu Y, Jiang M, Zhang D, Aobuliximu Y, et al. Distribution and Antibiotic Resistance Patterns of Pathogenic Bacteria in Patients With Chronic Cutaneous Wounds in China. *Front Med*. 2021 Mar 17;8:609584.
- Gottrup F, Apelqvist J, Bjarnsholt T, Cooper R, Moore Z, Peters E, et al. EWMA Document: Antimicrobials and Non-healing Wounds: Evidence, controversies and suggestions. *J Wound Care*. 2013 May;22(Sup5):S1–89.
- Lipsky BA, Dryden M, Gottrup F, Nathwani D, Seaton RA, Stryja J. Antimicrobial stewardship in wound care: A Position Paper from the British Society for Antimicrobial Chemotherapy and European Wound Management Association. *J Antimicrob Chemother*. 2016 Nov;71(11):3026–35.
- Heinzelmann M, Scott M, Lam T. Factors predisposing to bacterial invasion and infection. *Am J Surg*. 2002 Feb;183(2):179–90.
- European Wound Management Association (EWMA). Position Document: Identifying criteria for wound infection. In: EWMA Position Document. London: MEP Ltd; 2005. p. 2–5.
- Costerton JW, Stewart PS, Greenberg EP. Bacterial Biofilms: A Common Cause of Persistent Infections. *Science*. 1999 May 21;284(5418):1318–22.
- Hoiby N. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. A survey. *Acta Pathol Microbiol Scand Suppl*. 1977;(262):1–96.
- Marrie TJ, Nelligan J, Costerton JW. A scanning and transmission electron microscopic study of an infected endocardial pacemaker lead. *Circulation*. 1982 Dec;66(6):1339–41.
- Burmölle M, Thomsen TR, Fazli M, Dige I, Christensen L, Homøe P, et al. Biofilms in chronic infections – a matter of opportunity – monospecies biofilms in multispecies infections. *FEMS Immunol Med Microbiol*. 2010 Aug;59(3):324–36.
- Kolpen M, Kragh KN, Enciso JB, Faurholt-Jepsen D, Lindegaard B, Egelund GB, et al. Bacterial biofilms predominate in both acute and chronic human lung infections. *Thorax*. 2022 Jan 11;thoraxjnl-2021-217576.
- Bjarnsholt T, Jensen PO, Burmölle M, Hentzer M, Haagensen JAJ, Hougen HP, et al. Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. *Microbiology*. 2005 Feb 1;151(2):373–83.
- Bjarnsholt T, Ciofu O, Molin S, Givskov M, Hoiby N. Applying insights from biofilm biology to drug development — can a new approach be developed? *Nat Rev Drug Discov*. 2013 Oct;12(10):791–808.
- Schultz G, Bjarnsholt T, James GA, Leaper DJ, McBain AJ, Malone M, et al. Consensus guidelines for the identification and treatment of biofilms in chronic nonhealing wounds: Guidelines for chronic wound biofilms. *Wound Repair Regen*. 2017 Sep;25(5):744–57.
- Kirketerp-Møller K, Stewart PS, Bjarnsholt T. The zone model: A conceptual model for understanding the microenvironment of chronic wound infection. *Wound Repair Regen*. 2020 Sep;28(5):593–9.
- Cornforth DM, Dees JL, Ibberson CB, Huse HK, Mathiesen IH, Kirketerp-Møller K, et al. Pseudomonas aeruginosa transcriptome during human infection. *Proc Natl Acad Sci [Internet]*. 2018 May 29;115(22). Available from: <https://pnas.org/doi/full/10.1073/pnas.1717525115>
- Crabbé A, Jensen PØ, Bjarnsholt T, Coenye T. Antimicrobial Tolerance and Metabolic Adaptations in Microbial Biofilms. *Trends Microbiol*. 2019 Oct;27(10):850–63.
- Bjarnsholt T, Mastroianni E, Kirketerp-Møller K, Stewart PS, Mähr AM, Dominguez Cabañes A, et al. The impact of mental models on the treatment and research of chronic infections due to biofilms. *APMIS*. 2021 Oct;129(10):598–606.
- Coenye T, Goeres D, Van Bambeke F, Bjarnsholt T. Should standardized susceptibility testing for microbial biofilms be introduced in clinical practice? *Clin Microbiol Infect*. 2018 Jun;24(6):570–2.
- Brölmann FE, Ubink DT, Nelson EA, Munte K, van der Horst CMAM, Vermeulen H. Evidence-based decisions for local and systemic wound care. *Br J Surg*. 2012 Aug 2;99(9):1172–83.
- Dumville JC, Lipsky BA, Hoey C, Cruciani M, Fison M, Xia J. Topical antimicrobial agents for treating foot ulcers in people with diabetes. *Cochrane Wounds Group, editor. Cochrane Database Syst Rev [Internet]*. 2017 Jun 14; Available from: <https://doi.wiley.com/10.1002/14651858.CD011038.pub2>
- Koburger T, Hubner NO, Braun M, Siebert J, Kramer A. Standardized comparison of antiseptic efficacy of triclosan, PVP-iodine, octenidine dihydrochloride, polyhexanide and chlorhexidine digluconate. *J Antimicrob Chemother*. 2010 Aug 1;65(8):1712–9.
- Gemmel CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. *J Antimicrob Chemother*. 2006 Apr 1;57(4):589–608.
- Eron LJ. Managing skin and soft tissue infections: Expert panel recommendations on key decision points. *J Antimicrob Chemother*. 2003 Nov 1;52(900011):i3–17.
- Enzler MJ, Berbari E, Osmon DR. Antimicrobial Prophylaxis in Adults. *Mayo Clin Proc*. 2011 Jul;86(7):686–701.
- Lee DH, Vielmeyer O. Analysis of Overall Level of Evidence Behind Infectious Diseases Society of America Practice Guidelines. *Arch Intern Med [Internet]*. 2011 Jan 10;171(1). Available from: <http://archinte.jamanetwork.com/article.aspx?doi=10.1001/archinternmed.2010.482>
- Cooper C, Horner C, Barlow G, Stryja J, Sandy-Hodgetts K, Guise T, et al. A survey of practice and opinions on the use of topical antibiotics to prevent surgical site infection: More confusion than consensus. *J Antimicrob Chemother*. 2018 Jul 1;73(7):1978–83.
- Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: A cross-national database study. *The Lancet*. 2005 Feb;365(9459):579–87.

37. Hunter PA, Dawson S, French GL, Goossens H, Hawkey PM, Kuijper EJ, et al. Antimicrobial-resistant pathogens in animals and man: Prescribing, practices and policies. *J Antimicrob Chemother.* 2010 Feb 1;65(Supplement 1):i3–17.
38. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: Confronting the challenges of antibacterial discovery. *Nat Rev Drug Discov.* 2007 Jan;6(1):29–40.
39. Kolmos H. Bacteria and wound infections. In: *Wounds, background, diagnosis and treatment.* 2nd edn. Copenhagen: Munksgaard; 2008.
40. Lepointeur M, Royer G, Bourrel AS, Romain O, Dupont C, Doucet-Populaire F, et al. Prevalence of resistance to antiseptics and mupirocin among invasive coagulase-negative staphylococci from very preterm neonates in NICU: The creeping threat? *J Hosp Infect.* 2013 Apr;83(4):333–6.
41. McDonnell G, Russell AD. Antiseptics and Disinfectants: Activity, Action, and Resistance. *Clin Microbiol Rev.* 1999 Jan;12(1):147–79.
42. Maillard JY. Antimicrobial biocides in the healthcare environment: Efficacy, usage, policies, and perceived problems. *Ther Clin Risk Manag.* 2005 Dec;1(4):307–20.
43. Nikaido H. Multiple antibiotic resistance and efflux. *Curr Opin Microbiol.* 1998 Oct;1(5):516–23.
44. Lambert RJW, Joynson J, Forbes B. The relationships and susceptibilities of some industrial, laboratory and clinical isolates of *Pseudomonas aeruginosa* to some antibiotics and biocides. *J Appl Microbiol.* 2001 Dec;91(6):972–84.
45. Fraise AP. Susceptibility of antibiotic-resistant cocci to biocides. *J Appl Microbiol.* 2002;92 Suppl:158S–62S.
46. Levy SB. Active efflux, a common mechanism for biocide and antibiotic resistance. *Symp Ser Soc Appl Microbiol.* 2002;(31):65S–71S.
47. Suller MTE. Triclosan and antibiotic resistance in *Staphylococcus aureus*. *J Antimicrob Chemother.* 2000 Jul 1;46(1):11–8.
48. Narui K, Takano M, Noguchi N, Sasatsu M. Susceptibilities of Methicillin-Resistant *Staphylococcus aureus* Isolates to Seven Biocides. *Biol Pharm Bull.* 2007;30(3):585–7.
49. Russell AD. Introduction of biocides into clinical practice and the impact on antibiotic-resistant bacteria. *J Appl Microbiol.* 2002;92 Suppl:121S–35S.
50. Poole K. Efflux-mediated antimicrobial resistance. *J Antimicrob Chemother.* 2005 Jul 1;56(1):20–51.
51. Venter H, Henningsen ML, Begg SL. Antimicrobial resistance in healthcare, agriculture and the environment: The biochemistry behind the headlines. *Venter H, editor. Essays Biochem.* 2017 Mar 3;61(1):1–10.
52. Meyer B, Cookson B. Does microbial resistance or adaptation to biocides create a hazard in infection prevention and control? *J Hosp Infect.* 2010 Nov;76(3):200–5.
53. Pagès JM, Maillard JY, Davin-Regli A, Springthorpe S. Microbiocides – the double-edged sword: Environmental toxicity and emerging resistance. In: *Principles and practice of disinfection, preservation, and sterilization.* 5th ed. Chichester, West Sussex: John Wiley & Sons; 2012. p. 229–35.
54. Giuliano CA, Rybak MJ. Efficacy of Triclosan as an Antimicrobial Hand Soap and Its Potential Impact on Antimicrobial Resistance: A Focused Review. *Pharmacother J Hum Pharmacol Drug Ther.* 2015 Mar;35(3):328–36.
55. Lipsky BA, Senneville É, Abbas ZG, Aragón-Sánchez J, Diggle M, Embil JM, et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). *Diabetes Metab Res Rev.* 2020 Mar;36(S1):1–24.
56. Peters EJJ, Lipsky BA, Senneville É, Abbas ZG, Aragón-Sánchez J, Diggle M, et al. Interventions in the management of infection in the foot in diabetes: A systematic review. *Diabetes Metab Res Rev.* 2020 Mar;36(S1):1–15.
57. Percival SL, Woods E, Nutekpor M, Bowler P, Radford A, Cochrane C. Prevalence of silver resistance in bacteria isolated from diabetic foot ulcers and efficacy of silver-containing wound dressings. *Ostomy Wound Manage.* 2008 Mar;54(3):30–40.
58. Rayman G, Vas P, Dhatriya K, Driver V, Hartemann A, Londahl M, et al. Guidelines on use of interventions to enhance healing of chronic foot ulcers in diabetes (IWGDF 2019 update). *Diabetes Metab Res Rev.* 2020 Mar;36(S1):1–14.
59. Edmonds M, Foster A. The use of antibiotics in the diabetic foot. *Am J Surg.* 2004 May;187(5):S25–8.
60. Gardner SE, Frantz RA. Wound Bioburden and Infection-Related Complications in Diabetic Foot Ulcers. *Biol Res Nurs.* 2008 Jul;10(1):44–53.
61. Juli AB, Cullum N, Dumville JC, Westby MJ, Deshpande S, Walker N. Honey as a topical treatment for wounds. *Cochrane Wounds Group, editor. Cochrane Database Syst Rev [Internet].* 2015 Mar 6; Available from: <https://doi.wiley.com/10.1002/14651858.CD005083.pub4>
62. Game FL, Hinchliffe RJ, Apelqvist J, Armstrong DG, Bakker K, Hartemann A, et al. A systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes: Interventions for Healing Diabetic Foot Ulcers. *Diabetes Metab Res Rev.* 2012 Feb;28:119–41.
63. Martínez-De Jesús FR, Ramos-De la Medina A, Remes-Troche JM, Armstrong DG, Wu SC, Lázaro Martínez JL, et al. Efficacy and safety of neutral pH superoxidised solution in severe diabetic foot infections. *Int Wound J.* 2007 Oct 22;0(0):353–62.
64. Piaggese A, Goretti C, Mazzurco S, Tascini C, Leonildi A, Rizzo L, et al. A Randomized Controlled Trial to Examine the Efficacy and Safety of a New Super-Oxidized Solution for the Management of Wide Postsurgical Lesions of the Diabetic Foot. *Int J Low Extrem Wounds.* 2010 Mar;9(1):10–5.
65. Landsman A, Blume PA, Jordan DA, Vayser D, Gutierrez A. An Open-label, Three-arm Pilot Study of the Safety and Efficacy of Topical Microcyn Rx Wound Care versus Oral Levofloxacin versus Combined Therapy for Mild Diabetic Foot Infections. *J Am Podiatr Med Assoc.* 2011 Nov 1;101(6):484–96.
66. Hoogwerf CJ, Hop MJ, Nieuwenhuis MK, Oen IM, Middelkoop E, Van Baar ME. Topical treatment for facial burns. *Cochrane Wounds Group, editor. Cochrane Database Syst Rev.* 2020 Jul 29;2020(7):1–46.
67. Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. *BMJ.* 2010 Mar 23;340(mar23 1):c332–c332.
68. Jeffcoate WJ, Bus SA, Game FL, Hinchliffe RJ, Price PE, Schaper NC. Reporting standards of studies and papers on the prevention and management of foot ulcers in diabetes: Required details and markers of good quality. *Lancet Diabetes Endocrinol.* 2016 Sep;4(9):781–8.
69. Mills JL, Conte MS, Armstrong DG, Pomposelli FB, Schanzer A, Sidawy AN, et al. The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: Risk stratification based on Wound, Ischemia, and foot Infection (WIFI). *J Vasc Surg.* 2014 Jan;59(1):220–234.e2.
70. Tarricone A, Mata KDL, Gee A, Axman W, Buricea C, Mandato MG, et al. A Systematic Review and Meta-Analysis of the Effectiveness of LRINEC Score for Predicting Upper and Lower Extremity Necrotizing Fasciitis. *J Foot Ankle Surg.* 2022 Mar;61(2):384–9.
71. Knighton DR, Ciresi KF, Fiegel VD, Austin LL, Butler EL. Classification and Treatment of Chronic Nonhealing Wounds: *Ann Surg.* 1986 Sep;204(3):322–30.
72. Lipsky BA, Armstrong DG, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): Prospective, randomised, controlled, double-blinded, multicentre trial. *The Lancet.* 2005 Nov;366(9498):1695–703.
73. Lipsky BA, Itani K, Norden C, the Linezolid Diabetic Foot Infections Study Group. Treating Foot Infections in Diabetic Patients: A Randomized, Multicenter, Open-Label Trial of Linezolid versus Ampicillin-Sulbactam/Amoxicillin-Clavulanate. *Clin Infect Dis.* 2004 Jan;38(1):17–24.
74. Lipsky BA, A. D., Baker NR, Macdonald IA. Does a diabetic foot infection (DFI) wound score correlate with the clinical response to antibiotic treatment? Data from the SIDESTEP study. *Diabetologia.* 2005;(48 (Suppl. 1)).
75. Ge Y, MacDonald D, Henry MM, Hait HI, Nelson KA, Lipsky BA, et al. In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. *Diagn Microbiol Infect Dis.* 1999 Sep;35(1):45–53.
76. Moore DS, McCabe GP. *Introduction to the practice of statistics.* 5th. ed. New York: Freeman; 2006.
77. Gottrup F. Evidence Is a Challenge in Wound Management. *Int J Low Extrem Wounds.* 2006 Jun;5(2):74–5.
78. Bunnik EM, Aarts N. What do patients with unmet medical needs want? A qualitative study of patients' views and experiences with expanded access to unapproved, investigational treatments in the Netherlands. *BMC Med Ethics.* 2019 Dec;20(1):80.
79. World Health Organization. Patient safety [Internet]. 2019 [cited 2021 Aug 13]. Available from: <https://www.who.int/news-room/fact-sheets/detail/patient-safety>
80. Lior C, Bjerrum L. Antimicrobial resistance: Risk associated with antibiotic overuse and initiatives to reduce the problem. *Ther Adv Drug Saf.* 2014 Dec;5(6):229–41.
81. Stivers T. Managing Patient Pressure to Prescribe Antibiotics in the Clinic. *Pediatr Drugs.* 2021 Sep;23(5):437–43.
82. Sen CK. Human Wounds and Its Burden: An Updated Compendium of Estimates. *Adv Wound Care.* 2019 Feb;8(2):39–48.

83. Molina-Mula J, Gallo-Estrada J. Impact of Nurse-Patient Relationship on Quality of Care and Patient Autonomy in Decision-Making. *Int J Environ Res Public Health*. 2020 Jan 29;17(3):835.
84. Lindsay E, Remy R, Wilkie P, Valle F, White W, Maida V, et al. Patient-centred care: A call to action for wound management. *J Wound Care*. 2017 Nov 2;26(11):662–77.
85. Akhmetova A, Saliev T, Allan IU, Illsley MJ, Nurgozhin T, Mikhailovsky S. A Comprehensive Review of Topical Odor-Controlling Treatment Options for Chronic Wounds. *J Wound Ostomy Continence Nurs*. 2016 Nov;43(6):598–609.
86. Woo KY, Alam T, Marin J. Topical antimicrobial toolkit for wound infection. *Surg Technol Int*. 2014 Nov;25:45–52.
87. Krist AH, Tong ST, Aycock RA, Longo DR. Engaging Patients in Decision-Making and Behavior Change to Promote Prevention. *Stud Health Technol Inform*. 2017;240:284–302.
88. Guest JF, Fuller GW, Vowden P. Cohort study evaluating the burden of wounds to the UK's National Health Service in 2017/2018: Update from 2012/2013. *BMJ Open*. 2020 Dec;10(12):e045253.
89. Cheng Q, Lazzarini PA, Gibb M, Derhy PH, Kinnear EM, Burn E, et al. A cost-effectiveness analysis of optimal care for diabetic foot ulcers in Australia. *Int Wound J*. 2017 Aug;14(4):616–28.
90. Frykberg RG, Banks J. Challenges in the Treatment of Chronic Wounds. *Adv Wound Care*. 2015 Sep;4(9):560–82.
91. Cárdenas MK, Mirelman AJ, Galvin CJ, Lazo-Porras M, Pinto M, Miranda JJ, et al. The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru. *BMC Health Serv Res*. 2015 Jun;15(1):1–10.
92. Gönen M, Cakir M, Gonulalan G, Ozturk M, Ipekci S, Kosker A. The problems and cost-effectiveness analysis of diabetic foot infections. *Turk J Endocrinol Metab*. 2012;1(6):10–3.
93. Guest JF, Ayoub N, McIlwraith T, Uchegbu I, Gerrish A, Weidlich D, et al. Health economic burden that different wound types impose on the UK's National Health Service: Annual NHS cost of managing different wound types in the UK. *Int Wound J*. 2017 Apr;14(2):322–30.
94. Guest JF, Fuller GW, Vowden P. Diabetic foot ulcer management in clinical practice in the UK: Costs and outcomes. *Int Wound J*. 2018 Feb;15(1):43–52.
95. Chan B, Cadarette S, Wodchis W, Wong J, Mittmann N, Krahn M. Cost-of-illness studies in chronic ulcers: a systematic review. *J Wound Care*. 2017 Apr;26(sup4):S4–14.
96. Balderas-Peña LMA, Sat-Muñoz D, Ramírez-Conchas RE, Alvarado-Iñiguez MR, Garcia-de-Alba-García JE, Cruz-Corona E, et al. Descriptive, Longitudinal Study Results Applied to Statistical Models to Assess the Impact of Early Microbiological Cultures on the Economic Burden of Treatment for Infected Diabetic Foot Ulcers at a Mexican Public Health Facility. *Ostomy Wound Manage*. 2016 Dec;62(12):14–28.
97. Nussbaum SR, Carter MJ, Fife CE, DaVanzo J, Haight R, Nusgart M, et al. An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds. *Value Health J Int Soc Pharmacoeconomics Outcomes Res*. 2018 Jan;21(1):27–32.
98. Woods TJ, Tesfay F, Speck P, Kaambwa B. Economic evaluations considering costs and outcomes of diabetic foot ulcer infections: A systematic review. *Ferker B, editor. PLOS ONE*. 2020 Apr 30;15(4):e0232395.
99. Hicks CW, Selvarajah S, Mathioudakis N, Sherman RE, Hines KF, Black JH, et al. Burden of Infected Diabetic Foot Ulcers on Hospital Admissions and Costs. *Ann Vasc Surg*. 2016 May;33:149–58.
100. Health Quality Ontario. Hyperbaric Oxygen Therapy for the Treatment of Diabetic Foot Ulcers: A Health Technology Assessment. *Ont Health Technol Assess Ser*. 2017;17(5):1–142.
101. Liu S, He CZ, Cai YT, Xing QP, Guo YZ, Chen ZL, et al. Evaluation of negative-pressure wound therapy for patients with diabetic foot ulcers: Systematic review and meta-analysis. *Ther Clin Risk Manag*. 2017;13:533–44.
102. Saco M, Howe N, Nathoo R, Cherpelis B. Comparing the efficacies of alginate, foam, hydrocolloid, hydrofiber, and hydrogel dressings in the management of diabetic foot ulcers and venous leg ulcers: A systematic review and meta-analysis examining how to dress for success. *Dermatol Online J [Internet]*. 2016 Aug 19;22(8). Available from: <https://escholarship.org/uc/item/7ph5v17z>
103. Chow I, Lemos EV, Marr P, Machado M, Einarson TR. Pharmacoeconomic Analysis of Guidelines for Treating Mild Diabetic Foot Infections: A Decision-Tree Model for Canada. 2008;61(6):412–21.
104. Green W, Taylor M. Cost-Effectiveness Analysis of d-Nav for People with Diabetes at High Risk of Neuropathic Foot Ulcers. *Diabetes Ther Res Treat Educ Diabetes Relat Disord*. 2016 Sep;7(3):511–25.
105. N OD, Simon JM, Tomy S, R AP, V S. Appropriate empirical management of microbial infections in a tertiary care hospital: A cost-effectiveness approach. *Asian J Pharm Clin Res*. 2018 Feb 1;11(2):124–7.
106. Kirsner RS. Clinical evidence for and cost-effectiveness of advanced cellular tissue products for the treatment of diabetic foot ulcers. *Am J Manag Care*. 2018 Dec;24(14 Spec No.):SP607–8.
107. Goulionis JE, Vozikis A, Benos V, Nikolakis D. On the decision rules of cost-effective treatment for patients with diabetic foot syndrome. *Clin Outcomes Res CEOR*. 2010;2:121–6.
108. Malone M, West D, Xuan W, Lau NS, Maley M, Dickson HG. Outcomes and cost minimisation associated with outpatient parenteral antimicrobial therapy (OPAT) for foot infections in people with diabetes. *Diabetes Metab Res Rev*. 2015 Sep;31(6):638–45.
109. Gilligan AM, Waycaster CR, Landsman AL. Wound closure in patients with DFU: A cost-effectiveness analysis of two cellular/tissue-derived products. *J Wound Care*. 2015 Mar;24(3):149–56.
110. Guest JF, Singh H, Vowden P. Potential cost-effectiveness of using a collagen-containing dressing in managing diabetic foot ulcers in the UK. *J Wound Care*. 2018 Mar 2;27(3):136–44.
111. Lobmann R, Augustin M, Lawall H, Tigges W, Potempa C, Thiem H, et al. Cost-effectiveness of TLC-sucrose octasulfate versus control dressings in the treatment of diabetic foot ulcers. *J Wound Care*. 2019 Dec 2;28(12):808–16.
112. Romero Prada M, Roa C, Alfonso P, Acero G, Huérffano L, Vivas-Consuelo D. Cost-effectiveness analysis of the human recombinant epidermal growth factor in the management of patients with diabetic foot ulcers. *Diabet Foot Ankle*. 2018;9(1):1480249.
113. Tesar T, Szilberhorn L, Nemeth B, Nagy B, Wawruch M, Kalo Z. Cost-Utility Analysis of Heberprot-P as an Add-on Therapy to Good Wound Care for Patients in Slovakia with Advanced Diabetic Foot Ulcer. *Front Pharmacol*. 2017 Dec 22;8:946–51.
114. Wu B, Wan X, Ma J. Cost-effectiveness of prevention and management of diabetic foot ulcer and amputation in a health resource-limited setting. *J Diabetes*. 2018 Apr;10(4):320–7.
115. Piaggisi A, Láucli S, Bassetto F, Biedermann T, Marques A, Najafi B, et al. Advanced therapies in wound management: Cell and tissue based therapies, physical and bio-physical therapies smart and IT based technologies. *J Wound Care*. 2018 Jun 1;27(Sup6a):S1–137.
116. Massand S, Lewcun JA, LaRosa CA. Clinical and cost efficacy of advanced wound care matrices in the treatment of venous leg ulcers: A systematic review. *J Wound Care*. 2021 Jul 2;30(7):553–61.
117. Mairghani M, Jassim G, Elmusharaf K, Patton D, Eltahir O, Moore Z, et al. Methodological approaches for assessing the cost of diabetic foot ulcers: A systematic literature review. *J Wound Care*. 2019 May 2;28(5):261–6.
118. Ragnarson Tennvall G, Apelqvist J. Health-Economic Consequences of Diabetic Foot Lesions. *Clin Infect Dis*. 2004 Aug 1;39(Supplement_2):S132–9.
119. Schirr-Bonnans S, Costa N, Derumeaux-Burel H, Bos J, Lepage B, Garnault V, et al. Cost of diabetic eye, renal and foot complications: a methodological review. *Eur J Health Econ*. 2017 Apr;18(3):293–312.
120. Bouillet B, Meloni M, Ahluwalia R. Improving referral of patients with diabetic foot ulcer to specialised diabetes foot care units. *J Wound Care*. 2021 Oct 2;30(10):782–4.
121. Bouillet B, Ahluwalia R, Iacopi E, Garcia-Klepzig JL, Lüdemann C, Manu C, et al. Characteristics of new patient referrals to specialised diabetic foot units across Europe and factors influencing delays. *J Wound Care*. 2021 Oct 2;30(10):804–8.
122. Sánchez-Ríos JP, García-Klepzig JL, Manu C, Ahluwalia R, Lüdemann C, Meloni M, et al. Referral of patients with diabetic foot ulcers in four European countries: Patient follow-up after first GP visit. *J Wound Care*. 2019 Aug 1;28(Sup8):S4–14.
123. Manu C, Iacopi E, Bouillet B, Vouillarmet J, Ahluwalia R, Lüdemann C, et al. Delayed referral of patients with diabetic foot ulcers across Europe: Patterns between primary care and specialised units. *J Wound Care*. 2018 Mar 2;27(3):186–92.
124. Meloni M, Lazaro-Martínez JL, Ahluwalia R, Bouillet B, Izzo V, Di Venanzio M, et al. Effectiveness of fast-track pathway for diabetic foot ulcerations. *Acta Diabetol*. 2021 Oct;58(10):1351–8.
125. Wise J. Early referral for foot ulcers is vital, finds audit of diabetes care. *BMJ*. 2016 Mar 30;352:i1820.

126. Meloni M, Acquati S, Licciardello C, Ludovico O, Sepe M, Vermigli C, et al. Barriers to diabetic foot management in Italy: A multicentre survey in diabetic foot centres of the Diabetic Foot Study Group of the Italian Society of Diabetes (SID) and Association of Medical Diabetologists (AMD). *Nutr Metab Cardiovasc Dis*. 2021 Mar;31(3):776–81.
127. Moore Z, Avsar P, Wilson P, Mairighani M, O'Connor T, Nugent L, et al. Diabetic foot ulcers: treatment overview and cost considerations. *J Wound Care*. 2021 Oct 2;30(10):786–91.
128. European Commission. A European One Health Action Plan against Antimicrobial Resistance. https://ec.europa.eu/health/system/files/2020-01/amr_2017_action-plan_0.pdf. 2017.
129. HM Government. Tackling antimicrobial resistance 2019–2024 – The UK's five-year national action plan. 2019 Apr;101(4):426–7.
130. World Health Organization. Global action plan on antimicrobial resistance [Internet]. Geneva: World Health Organization; 2015 [cited 2022 Jan 21]. 28 p. Available from: <https://apps.who.int/iris/handle/10665/193736>
131. World Health Organization. Antibiotic resistance [Internet]. 2020 [cited 2022 May 12]. Available from: <https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance>
132. International Wound Infection Institute (IWII). Wound infection in clinical practice. 3rd ed. London: Wounds International; 2022.
133. World Health Organization. Antimicrobial resistance fact sheet [Internet]. 2021 [cited 2022 Aug 2]. Available from: <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>
134. The Association for Professionals in Infection Control and Epidemiology (APIC). Antimicrobial stewardship [Internet]. APIC. 2021 [cited 2022 Aug 2]. Available from: <https://apic.org/professional-practice/practice-resources/antimicrobial-stewardship/>
135. Uçkay I, Berli M, Sendi P, Lipsky BA. Principles and practice of antibiotic stewardship in the management of diabetic foot infections. *Curr Opin Infect Dis*. 2019 Apr;32(2):95–101.
136. Guest JF, Fuller GW, Vowden P. Venous leg ulcer management in clinical practice in the UK: Costs and outcomes: Health economic impact of VLUs in the UK. *Int Wound J*. 2018 Feb;15(1):29–37.
137. Guest JF, Ayoub N, McIlwraith T, Uchegbu I, Gerrish A, Weidlich D, et al. Health economic burden that wounds impose on the National Health Service in the UK. *BMJ Open*. 2015 Dec;5(12):e009283.
138. O'Neill J. Tackling drug-resistant infections globally: Final report and recommendations. Review on Antimicrobial Resistance [Internet]. 2016 [cited 2022 Jan 21]; Available from: https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf
139. Cooper R, Kirketerp-Møller K. Non-antibiotic antimicrobial interventions and antimicrobial stewardship in wound care. *J Wound Care*. 2018 Jun 2;27(6):355–77.
140. Lachapelle JM. Antiseptics and Disinfectants. In: John SM, Johansen JD, Rustermeier T, Elsner P, Maibach HI, editors. *Kanerva's Occupational Dermatology* [Internet]. Cham: Springer International Publishing; 2020 [cited 2022 Aug 2]. p. 493–506. Available from: http://link.springer.com/10.1007/978-3-319-68617-2_36
141. Siaw-Sakyi V. Early wound infection identification using the WIRE tool in community health care settings: An audit report. *Br J Community Nurs*. 2017 Dec 1;22(Sup12):S20–7.
142. Stryja J, Sandy-Hodgetts K, Collier M, Moser C, Ousey K, Probst S, et al. Surgical site infection: Preventing and managing surgical site infection across health care sectors. *J Wound Care*. 2020 Feb 1;29(Sup2b):S1–72.
143. Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. *Lancet Lond Engl*. 2016 Jan 9;387(10014):176–87.
144. Transatlantic Taskforce on Antimicrobial Resistance: Progress report. Recommendations for future collaboration between the US and EU [Internet]. 2014 [cited 2022 Jan 21]. Available from: https://www.cdc.gov/drugresistance/pdf/TATFAR-Progress_report_2014.pdf
145. Global Antibiotic Resistance Partnership (GARP) [Internet]. CDDP. [cited 2022 Jan 21]. Available from: <https://cddp.org/projects/global-antibiotic-resistance-partnership/>
146. Global Health security agenda [Internet]. [cited 2022 Jan 21]. Available from: <https://ghsagenda.org/>
147. OIE, FAO and WHO enlarge their collaboration commitment to face health challenges [Internet]. WOA - World Organisation for Animal Health. 2017 [cited 2022 Aug 2]. Available from: <https://www.woah.org/en/oie-fao-and-who-enlarge-their-collaboration-commitment-to-face-health-challenges/>
148. World Antimicrobial Awareness Week 2020 - Handle with care: United to preserve antimicrobials [Internet]. [cited 2022 Aug 2]. Available from: <https://www.who.int/news-room/events/detail/2020/11/18/default-calendar/world-antimicrobial-awareness-week-2020>
149. Öien RF, Forssell HW. Ulcer healing time and antibiotic treatment before and after the introduction of the Registry of Ulcer Treatment: An improvement project in a national quality registry in Sweden. *BMJ Open*. 2013 Aug;3(8):e003091.
150. Sibbald RG, Elliott JA, Persaud-Jaimangal R, Goodman L, Armstrong DG, Harley C, et al. Wound Bed Preparation 2021. *Adv Skin Wound Care*. 2021 Apr 1;34(4):183–95.
151. Axel K. Case for wound cleansing. *J Wound Care*. 2020 Oct 1;29(Sup10a):S3–4.
152. Ierano C, Nankervis JAM, James R, Rajkhowa A, Peel T, Thursky K. Surgical antimicrobial prophylaxis. *Aust Prescr*. 2017 Dec;40(6):225–9.
153. World Health Organization. Regional Office for Europe, European Observatory on Health Systems and Policies, Mossialos E, Morel CM, Edwards S, Berenson J, et al. Policies and incentives for promoting innovation in antibiotic research [Internet]. Copenhagen: World Health Organization. Regional Office for Europe; 2010. Available from: <https://apps.who.int/iris/handle/10665/326376>
154. Lee BY. The wound management manual. New York: McGraw-Hill; 2005.

WAX

